Ristocetin

Jump to navigation Jump to search

WikiDoc Resources for Ristocetin

Articles

Most recent articles on Ristocetin

Most cited articles on Ristocetin

Review articles on Ristocetin

Articles on Ristocetin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ristocetin

Images of Ristocetin

Photos of Ristocetin

Podcasts & MP3s on Ristocetin

Videos on Ristocetin

Evidence Based Medicine

Cochrane Collaboration on Ristocetin

Bandolier on Ristocetin

TRIP on Ristocetin

Clinical Trials

Ongoing Trials on Ristocetin at Clinical Trials.gov

Trial results on Ristocetin

Clinical Trials on Ristocetin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ristocetin

NICE Guidance on Ristocetin

NHS PRODIGY Guidance

FDA on Ristocetin

CDC on Ristocetin

Books

Books on Ristocetin

News

Ristocetin in the news

Be alerted to news on Ristocetin

News trends on Ristocetin

Commentary

Blogs on Ristocetin

Definitions

Definitions of Ristocetin

Patient Resources / Community

Patient resources on Ristocetin

Discussion groups on Ristocetin

Patient Handouts on Ristocetin

Directions to Hospitals Treating Ristocetin

Risk calculators and risk factors for Ristocetin

Healthcare Provider Resources

Symptoms of Ristocetin

Causes & Risk Factors for Ristocetin

Diagnostic studies for Ristocetin

Treatment of Ristocetin

Continuing Medical Education (CME)

CME Programs on Ristocetin

International

Ristocetin en Espanol

Ristocetin en Francais

Business

Ristocetin in the Marketplace

Patents on Ristocetin

Experimental / Informatics

List of terms related to Ristocetin


Ristocetin is an antibiotic, obtained from Amycolatopsis lurida, previously used to treat staphylococcal infections. It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro, e.g. to diagnose von Willebrand disease (vWD) or the Bernard-Soulier syndrome. Platelet agglutination caused by ristocetin can occur only in the presence of large multimers of von Willebrand factor, so if ristocetin is added to blood lacking the factor (or its receptor -- see below), it will not coagulate.

In some types of vWD (types 2B and platelet-type), lower than normal amounts of ristocetin cause platelet aggregation when the patient's platelet-rich plasma is used.[1] This paradox is explained by these types having gain-of-function mutations which cause the vWD high molecular-weight multimers to bind more tightly to their receptors on platelets (the alpha chains of glycoprotein Ib (GPIb) receptors). In the case of type 2B vWD, the gain-of-function mutation involves von Willebrand's factor (VWF gene), and in platelet-type vWD, the receptor is the object of the mutation (GPIb). This increased binding causes vWD because the high-molecular weight multimers are removed from circulation in plasma since they remain attached to the patient's platelets. Thus, if the patient's platelet-poor plasma is used, the ristocetin cofactor assay will not agglutinate "standardized (ie., pooled platelets from normal donors which are fixed in formalin)" platelets, similar to the other types of vWD.

In all forms of the ristocetin assay, the platelets are fixed in formalin prior to the assay to prevent von Willebrand's factor stored in platelet granules from being released and participating in platelet aggregation. Thus, the ristocetin cofactor activity depends only upon high-molecular multimers of the factor present in circulating plasma.

References

  1. McPherson, Richard A. (2006). Henry's Clinical Diagnosis and Management by Laboratory Methods. Philadelphia: W. B. Saunders. pp. pp. 760–2. ISBN 978-1416002871. Unknown parameter |coauthors= ignored (help)


de:Ristocetin

Template:WH Template:WS